News | May 06, 2011

African Americans Experience Worse Long-Term Outcomes After PCI

May 6, 2011 – African American patients who undergo angioplasty and stenting fare worse over the long run than patients of other races, regardless of socioeconomic status. In fact, the risk of dying within about three years is more than twice as high among African Americans, according to a study presented today at the Society for Cardiovascular Angiography and Interventions (SCAI) 2011 Scientific Sessions.

“We need to channel healthcare resources to effectively treat this vulnerable population,” said Steve Attanasio, D.O., an interventional cardiology fellow at Rush University Medical Center in Chicago. “It’s very worrisome that the first major cardiac problem many of these patients experience following coronary intervention is death.”

The study focused on 1,432 consecutive patients who had percutaneous coronary intervention (PCI) at John H. Stroger, Jr. Hospital of Cook County in Chicago and received follow-up within the same public health system. The patients were relatively young (57-years-old on average). They were also relatively high-risk: Only about 30 percent had a pre-scheduled procedure for stable coronary disease, while the remaining 70 percent needed urgent PCI because of a heart attack or unstable chest pain.

After an average follow-up of 2.7 years, the combined rate of survival without heart attack or need for a repeat procedure in the treated artery was 78 percent among African American patients, as compared with 86 percent among patients of another race (p=0.001). The overall death rate at 2.7 years was 8.6 percent; however, among African Americans, it spiked to 12.1 percent, as compared with 5 percent among other patients (p

The reason for the increased risk among African Americans is not yet known, though many things may play a role, including poorly understood genetic and sociocultural factors. But the importance of aggressively treating risk factors such as diabetes, high blood pressure, high cholesterol and smoking is clear, as is the need to educate patients about a heart-healthy lifestyle.

“The ultimate goal is prevention,” Attanasio said. “We need to reach out not only to patients but also to healthcare providers. It’s not enough to perform a stenting procedure. These patients require close follow-up.”

This study received no outside funding.

For more information: www.scai.org, www.SecondsCount.org


Related Content

News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
News | Cardiovascular Clinical Studies

Jan. 13, — A new cohort study among 103,642 adults found that current use of cigars was associated with increased risk ...

Home January 14, 2025
Home
News | Cardiovascular Clinical Studies

Nov. 22, 2024 — BridgeBio Pharma, Inc. recently announced that the U.S. Food and Drug Administration (FDA) approved ...

Home November 25, 2024
Home
News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
Subscribe Now